The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $11.03

Today's change0.00 0.00%
Updated July 27 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $11.03

Today's change0.00 0.00%
Updated July 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Vanda Pharmaceuticals Inc closed at (U.S.)$11.03.

Over the last five days, shares have lost 10.18% and are down 22.97% for the last year to date. This security has underperformed the S&P 500 by 26.73% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $11.03
  • High--
  • Low--
  • Bid / Ask(U.S.) $10.50 / (U.S.) $0.00
  • YTD % change-22.97%
  • Volume0
  • Average volume (10-day)509,648
  • Average volume (1-month)596,673
  • Average volume (3-month)853,431
  • 52-week range(U.S.) $8.34 to (U.S.) $15.51
  • Beta1.85
  • Trailing P/E13.00×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.85
Updated July 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+57.78%

Based on its net profit margin of 57.78%, Vanda Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue22151511
Total other revenue--------
Total revenue22151511
Gross profit17151411
Total cost of revenue5110
Total operating expense32-541632
Selling / general / administrative19171128
Research & development4544
Depreciation / amortization4111
Interest expense (income), net operating--------
Unusual expense (income)---78----
Other operating expenses, total--------
Operating income-1070-1-22
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-1070-1-22
Income after tax-1070-1-22
Income tax, total--000
Net income-1070-1-22
Total adjustments to net income--------
Net income before extra. items-1070-1-22
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1070-1-22
Inc. avail. to common incl. extra. items-1070-1-22
Diluted net income-1070-1-22
Dilution adjustment00--0
Diluted weighted average shares42393434
Diluted EPS excluding extraordinary itemsvalue per share-0.241.77-0.04-0.64
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.24-0.20-0.04-0.64